24
Participants
Start Date
July 31, 2015
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
Ibuprofen
On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Laureate Institute for Brain Research, Tulsa
Lead Sponsor
University of Oklahoma
OTHER
Laureate Institute for Brain Research, Inc.
OTHER